Featured Research

from universities, journals, and other organizations

Experts question whether preventive drugs are value for money

Date:
April 19, 2011
Source:
BMJ-British Medical Journal
Summary:
Writing in a new article, experts challenge the view that popular drugs to prevent disease -- like statins and anti-hypertensives to prevent heart disease and stroke, or bisphosphonates to prevent fractures -- represent value for money.

Experts are challenging the view that popular drugs to prevent disease -- like statins and antihypertensives to prevent heart disease and stroke, or bisphosphonates to prevent fractures -- represent value for money.

In a paper published online in the British Medical Journal, Teppo Jδrvinen and colleagues argue that the benefits seen when these drugs are tested in clinical trials may not apply in the real world.

They argue that value for money in real life clinical practice is likely to be much lower than in a clinical trial, where patients are carefully selected and receive special attention from dedicated staff. "This gap between the ideal and clinical circumstances raises the question of how well our most widely used preventive drugs work in real life," they write.

For example, data from randomised trials suggest that bisphosphonates are a cost effective way to prevent hip fractures in older people. But this is a far cry from reality, say the authors.

Using 2003 data on 7411 hip fractures in Finland, they estimate that giving bisphosphonates to all 1.86 million citizens aged 50 years and over would only guarantee prevention of 343 fractures.

"Thus, although there are claims that important preventive drugs such as statins, antihypertensives, and bisphosphonates are cost effective, there are no valid data on the effectiveness, and particularly the cost effectiveness, in usual clinical care," they say.

Despite this dearth of data, they point out that the majority of clinical guidelines and recommendations for preventive drug therapy rest on these claims.

The authors argue that before claims on cost effectiveness can be used to guide treatment policies and practices, it should be adequately proven by testing in a real-world setting.

"We need to put an end to this kind of gaming of the system and start to advocate true comparative effectiveness research," they conclude. "Unless this is done, the important question whether preventive pharmacotherapy is cost effective will remain unanswered."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. L. N. Jarvinen, H. Sievanen, P. Kannus, J. Jokihaara, K. M. Khan. The true cost of pharmacological disease prevention. BMJ, 2011; 342 (apr19 1): d2175 DOI: 10.1136/bmj.d2175

Cite This Page:

BMJ-British Medical Journal. "Experts question whether preventive drugs are value for money." ScienceDaily. ScienceDaily, 19 April 2011. <www.sciencedaily.com/releases/2011/04/110419205723.htm>.
BMJ-British Medical Journal. (2011, April 19). Experts question whether preventive drugs are value for money. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/04/110419205723.htm
BMJ-British Medical Journal. "Experts question whether preventive drugs are value for money." ScienceDaily. www.sciencedaily.com/releases/2011/04/110419205723.htm (accessed July 30, 2014).

Share This




More Science & Society News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Britain Testing Driverless Cars on Roadways

Britain Testing Driverless Cars on Roadways

AP (July 30, 2014) — British officials said on Wednesday that driverless cars will be tested on roads in as many as three cities in a trial program set to begin in January. Officials said the tests will last up to three years. (July 30) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
China's Drone King Says the Revolution Depends on Regulators

China's Drone King Says the Revolution Depends on Regulators

Reuters - Business Video Online (July 30, 2014) — Comparing his current crop of drones to early personal computers, DJI founder Frank Wang says the industry is poised for a growth surge - assuming regulators in more markets clear it for takeoff. Jon Gordon reports. Video provided by Reuters
Powered by NewsLook.com
London Mayor Outlines 50-Year Vision Ahead of Population Rise

London Mayor Outlines 50-Year Vision Ahead of Population Rise

AFP (July 30, 2014) — London Mayor Boris Johnson outlined his infrastructure plan for the British capital over the next 50 years on Wednesday, with a focus on how to cope with a population expected to reach 11 million. Duration: 00:57 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins